Shield Therapeutics (LON:STX) Stock Price Up 10.3% - Still a Buy?

Key Points

• Shield Therapeutics' stock surged 10.3% on Monday, trading at GBX 8.60 after hitting a high of GBX 9, with a significant trading volume increase of 84% from its average.
• Analysts remain optimistic, as Peel Hunt reissued a “buy” rating with a price target of GBX 15, contributing to a consensus rating of “Buy” for the stock.
• Shield Therapeutics specializes in selling Accrufer®/Feraccru®, a treatment for iron deficiency, addressing a major need in the healthcare market.

Shares of Shield Therapeutics plc (LON:STX - Get Free Report) shot up 10.3% on Monday . The stock traded as high as GBX 9 ($0.12) and last traded at GBX 8.60 ($0.12). 5,192,013 shares changed hands during trading, an increase of 84% from the average session volume of 2,819,035 shares. The stock had previously closed at GBX 7.80 ($0.11).

Wall Street Analyst Weigh In

Separately, Peel Hunt reissued a "buy" rating and issued a GBX 15 price target on shares of Shield Therapeutics in a research note on Wednesday, October 1st. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Shield Therapeutics presently has a consensus rating of "Buy" and a consensus target price of GBX 15.

Shield Therapeutics Price Performance

The company's 50-day moving average price is GBX 6.81 and its 200-day moving average price is GBX 4.18. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The firm has a market cap of £91.32 million, a price-to-earnings ratio of -430.00 and a beta of 1.42.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.